会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 26. 发明授权
    • 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
    • 1H-吡咯并[2,3-D]嘧啶衍生物及其使用方法
    • US07429596B2
    • 2008-09-30
    • US10871732
    • 2004-06-18
    • Masahiro TanakaChao ZhangKevan M. ShokatAlma L. BurlingameKirk HansenRaynard L. BatemanStephen G. DiMagno
    • Masahiro TanakaChao ZhangKevan M. ShokatAlma L. BurlingameKirk HansenRaynard L. BatemanStephen G. DiMagno
    • C07D487/04C07D413/06A61K31/519A61K31/675A61K31/662A61K31/497A61K31/5355C07F9/38A61P35/04A61P35/02
    • C07D487/04
    • This invention generally relates to pyrazolo pyrimidine derivatives useful as inhibitors of short chain dehydrogenase/reductase (SDR) family of NAD(P)(H) dependent oxido-reductases. The invention further relates to pharmaceutical compositions and methods of preventing or treating disease with 1H-Pyrrolo[2.3-d]pyrimidine derivatives. More specifically, the invention relates to a 1H-Pyrrolo[2.3-d]pyrimidine which is a compound of Formula I or II: or a pharmaceutically-acceptable salt or prodrug thereof; wherein: Y is N or CR5; Z is NR3R4, halo, H, OH, alkyl, alkyloxy, or haloalkyl; and R1a is indolyl, thiazolyl, benzyl, biphenylyl, thiophenyl, pyrrolyl, or phenyl, wherein said phenyl is substituted with at least one of OH, —NR3R4, —C(═O)NR6R7, —CN, NO2—C(═O)OH, —C(═O)O-alkyl, (C1-C4)alkyl, halo, haloalkyl or haloaryl; and wherein said indolyl, thiazolyl, benzyl, biphenylyl, thiophenyl, or pyrrolyl is optionally substituted with OH, —NR3R4, —C(═O)NR6R7, —CN, NO2, —C(═O)O—R3, (C1-C4)alkyl, halo, haloalkyl or haloaryl.
    • 本发明一般涉及可用作NAD(P)(H)依赖性氧化还原酶的短链脱氢酶/还原酶(SDR)家族的抑制剂的吡唑并嘧啶衍生物。 本发明还涉及用1H-吡咯并[2,3-d]嘧啶衍生物预防或治疗疾病的药物组合物和方法。 更具体地,本发明涉及作为式I或II化合物的1H-吡咯并[2,3-d]嘧啶或其药学上可接受的盐或前药; 其中:Y是N或CR 5; Z是NR 3 R 4,卤素,H,OH,烷基,烷氧基或卤代烷基; 并且R 1a是吲哚基,噻唑基,苄基,联苯基,噻吩基,吡咯基或苯基,其中所述苯基被OH,-NR 3 R 3中的至少一个取代, -C(-O)NR 6 R 7,-CN,NO 2 -C(-O(O) )OH,-C(-O)O-烷基,(C 1 -C 4 -C 4)烷基,卤素,卤代烷基或卤代芳基; 并且其中所述吲哚基,噻唑基,苄基,联苯基,噻吩基或吡咯基任选被OH,-NR 3 R 4,-C( - )NR -C(O)OR 3,-C(-O)OR 3,(C 1 -C 6) C 1 -C 4烷基,卤素,卤代烷基或卤代芳基。
    • 27. 发明申请
    • Selective serine/threonine kinase inhibitors
    • 选择性丝氨酸/苏氨酸激酶抑制剂
    • US20070082884A1
    • 2007-04-12
    • US10552847
    • 2004-04-12
    • Jack TauntonMichael CohenKevan ShokatChao Zhang
    • Jack TauntonMichael CohenKevan ShokatChao Zhang
    • A61K31/55A61K31/519A61K31/517A61K31/407A61K31/404
    • C07D487/04
    • Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at least one nitrogen ring atom, and an electrophilic substituent that is capable of reacting with a cysteine residue within the ATP binding site of a kinase. Preferred compounds include certain pyrrolopyrimidines and oxindoles having such an electrophilic substituent and optionally an aromatic or heteroaromatic substituent that is capable of interacting with a threonine or smaller residue located in the gatekeeper position of the kinase. Kinases lacking such cysteine residues may be engineered or modified so that they are capable of being inhibited by such compounds by replacing a valine or other amino acid residue within the ATP binding site by a cysteine residue.
    • 在ATP结合位点内具有一个或多个半胱氨酸残基的蛋白激酶的抑制通过使本身或细胞或受试者中的激酶与抑制有效量的具有由两个或更多个的杂环核心结构组成的化合物接触来实现 含有至少一个氮环原子的稠环,以及能够与激酶的ATP结合位点内的半胱氨酸残基反应的亲电取代基。 优选的化合物包括具有这样的亲电子取代基的某些吡咯并嘧啶和羟吲哚,以及任选的能够与位于激酶的关守位置的苏氨酸或更小残基相互作用的芳族或杂芳族取代基。 缺乏这种半胱氨酸残基的激酶可以被改造或修饰,使得它们能够被这种化合物抑制,通过用半胱氨酸残基替换ATP结合位点内的缬氨酸或其它氨基酸残基。